335 related articles for article (PubMed ID: 17143067)
1. The role of the renal kallikrein-kinin system in diabetic nephropathy.
Riad A; Zhuo JL; Schultheiss HP; Tschöpe C
Curr Opin Nephrol Hypertens; 2007 Jan; 16(1):22-6. PubMed ID: 17143067
[TBL] [Abstract][Full Text] [Related]
2. The kallikrein-kinin system in diabetic kidney disease.
Liu W; Stanton RC; Zhang Z
Curr Opin Nephrol Hypertens; 2017 Sep; 26(5):351-357. PubMed ID: 28538015
[TBL] [Abstract][Full Text] [Related]
3. The kallikrein-kinin system, angiotensin converting enzyme inhibitors and insulin sensitivity.
Damas J; Garbacki N; Lefèbvre PJ
Diabetes Metab Res Rev; 2004; 20(4):288-97. PubMed ID: 15250031
[TBL] [Abstract][Full Text] [Related]
4. The kallikrein-kinin system in diabetic nephropathy.
Tomita H; Sanford RB; Smithies O; Kakoki M
Kidney Int; 2012 Apr; 81(8):733-44. PubMed ID: 22318421
[TBL] [Abstract][Full Text] [Related]
5. Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature.
Tsuchida S; Miyazaki Y; Matsusaka T; Hunley TE; Inagami T; Fogo A; Ichikawa I
Kidney Int; 1999 Aug; 56(2):509-16. PubMed ID: 10432390
[TBL] [Abstract][Full Text] [Related]
6. The plasma and tissue kininogen-kallikrein-kinin system: role in the cardiovascular system.
Marcondes S; Antunes E
Curr Med Chem Cardiovasc Hematol Agents; 2005 Jan; 3(1):33-44. PubMed ID: 15638742
[TBL] [Abstract][Full Text] [Related]
7. Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.
Tschöpe C; Seidl U; Reinecke A; Riester U; Graf K; Schultheiss HP; Hilgenfeldt U; Unger T
Int Immunopharmacol; 2003 Mar; 3(3):335-44. PubMed ID: 12639811
[TBL] [Abstract][Full Text] [Related]
8. The kallikrein-kinin system in diabetic retinopathy: lessons for the kidney.
Phipps JA; Feener EP
Kidney Int; 2008 May; 73(10):1114-9. PubMed ID: 18272958
[TBL] [Abstract][Full Text] [Related]
9. Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT1 receptor blockade.
Tschöpe C; Schultheiss HP; Walther T
J Cardiovasc Pharmacol; 2002 Apr; 39(4):478-87. PubMed ID: 11904521
[TBL] [Abstract][Full Text] [Related]
10. Towards understanding the kallikrein-kinin system: insights from measurement of kinin peptides.
Campbell DJ
Braz J Med Biol Res; 2000 Jun; 33(6):665-77. PubMed ID: 10829095
[TBL] [Abstract][Full Text] [Related]
11. Cardioprotective mechanisms of the kallikrein-kinin system in diabetic cardiopathy.
Spillmann F; Van Linthout S; Schultheiss HP; Tschöpe C
Curr Opin Nephrol Hypertens; 2006 Jan; 15(1):22-9. PubMed ID: 16340662
[TBL] [Abstract][Full Text] [Related]
12. Cardioprotection and kallikrein-kinin system in acute myocardial ischaemia in mice.
Messadi-Laribi E; Griol-Charhbili V; Gaies E; Vincent MP; Heudes D; Meneton P; Alhenc-Gelas F; Richer C
Clin Exp Pharmacol Physiol; 2008 Apr; 35(4):489-93. PubMed ID: 18307747
[TBL] [Abstract][Full Text] [Related]
13. Novel anti-thrombotic mechanisms mediated by Mas receptor as result of balanced activities between the kallikrein/kinin and the renin-angiotensin systems.
Fang C; Schmaier AH
Pharmacol Res; 2020 Oct; 160():105096. PubMed ID: 32712319
[TBL] [Abstract][Full Text] [Related]
14. Kinin-related effects of angiotensin-converting enzyme inhibition.
Bönner G
Clin Physiol Biochem; 1990; 8 Suppl 1():6-15. PubMed ID: 2257722
[TBL] [Abstract][Full Text] [Related]
15. Kallikrein(K1)-kinin-kininase (ACE) and end-organ damage in ischemia and diabetes: therapeutic implications.
Desposito D; Waeckel L; Potier L; Richer C; Roussel R; Bouby N; Alhenc-Gelas F
Biol Chem; 2016 Dec; 397(12):1217-1222. PubMed ID: 27622831
[TBL] [Abstract][Full Text] [Related]
16. Kinin receptor agonism restores hindlimb postischemic neovascularization capacity in diabetic mice.
Desposito D; Potier L; Chollet C; Gobeil F; Roussel R; Alhenc-Gelas F; Bouby N; Waeckel L
J Pharmacol Exp Ther; 2015 Feb; 352(2):218-26. PubMed ID: 25398240
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic targets and prototype therapeutics in the kallikrein-kinin system: bradykinin receptor agonists or antagonists.
Sharma JN; Al-Sherif GJ
ScientificWorldJournal; 2006 Oct; 6():1247-61. PubMed ID: 17041716
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological enhancement of the kallikrein-kinin system promotes anti-fibrotic responses in human mesangial cells.
Pawluczyk IZ; Patel SR; Harris KP
Cell Physiol Biochem; 2006; 18(6):327-36. PubMed ID: 17170519
[TBL] [Abstract][Full Text] [Related]
19. Is there a role for bradykinin in the therapeutic and side effects of angiotensin-converting enzyme inhibitors?
Marceau F
Can J Cardiol; 1997 Feb; 13(2):187-94. PubMed ID: 9070170
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular properties of the kallikrein-kinin system.
Sharma JN; Sharma J
Curr Med Res Opin; 2002; 18(1):10-7. PubMed ID: 11999140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
